Global Finance News
30 Oct 2025, 14:12
Merck Reports Solid Q3 Results and Raises 2025 Outlook on Strong Oncology and New Product Performance
Merck & Co. (NYSE: MRK) posted third-quarter 2025 revenue of $17.3 billion, up 4% year over year, driven by continued strength in oncology and animal health. KEYTRUDA sales rose 10% to $8.1 billion, WINREVAIR surged 141% to $360 million, and CAPVAXIVE contributed $244 million in its launch quarter. GAAP EPS climbed 87% to $2.32, while non-GAAP EPS increased 64% to $2.58. The company raised its full-year sales outlook to $64.5–$65.0 billion and narrowed non-GAAP EPS guidance to $8.93–$8.98.
Merck highlighted major milestones, including FDA approval of subcutaneous KEYTRUDA QLEX, positive Phase 3 results for Enlicitide Decanoate in hypercholesterolemia, and the completion of its acquisition of Verona Pharma, strengthening its respiratory portfolio.
Merck & Co. (NYSE: MRK) posted third-quarter 2025 revenue of $17.3 billion, up 4% year over year, driven by continued strength in oncology and animal health. KEYTRUDA sales rose 10% to $8.1 billion, WINREVAIR surged 141% to $360 million, and CAPVAXIVE contributed $244 million in its launch quarter. GAAP EPS climbed 87% to $2.32, while non-GAAP EPS increased 64% to $2.58. The company raised its full-year sales outlook to $64.5–$65.0 billion and narrowed non-GAAP EPS guidance to $8.93–$8.98.
Merck highlighted major milestones, including FDA approval of subcutaneous KEYTRUDA QLEX, positive Phase 3 results for Enlicitide Decanoate in hypercholesterolemia, and the completion of its acquisition of Verona Pharma, strengthening its respiratory portfolio.